The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AKBA | +91.77% | -4.72% | -0.96% | -89% |
| S&P | +16.9% | +95.99% | +14.39% | +263% |
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
An approval in the U.K. for Akebia's symptomatic anemia therapy boosted the stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $62.47M | 43.1% |
| Gross Profit | $52.24M | 99.4% |
| Gross Margin | 83.62% | 23.6% |
| Market Cap | $956.00M | 347.2% |
| Market Cap / Employee | $5.28M | 0.0% |
| Employees | 181 | 8.4% |
| Net Income | $0.25M | 102.9% |
| EBITDA | $14.41M | 2002.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $137.31M | 247.6% |
| Accounts Receivable | $72.81M | 144.6% |
| Inventory | 16.7 | -30.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $178.10M | 82.8% |
| Short Term Debt | $32.46M | 351.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -12.90% | 4.2% |
| Return On Invested Capital | -102.52% | 0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $22.22M | 320.1% |
| Operating Free Cash Flow | $22.35M | 322.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -5.54 | -7.97 | -8.78 | 38.74 | -594.33% |
| Price to Sales | 1.63 | 2.59 | 2.51 | 4.84 | 295.14% |
| Price to Tangible Book Value | -2.36 | -3.39 | -3.99 | -27.64 | 1365.97% |
| Enterprise Value to EBITDA | -138.86 | -730.77 | 40.26 | 73.59 | -81.93% |
| Total Debt | $191.13M | $194.65M | $206.17M | $210.56M | 101.25% |
AKBA earnings call for the period ending September 30, 2021.
AKBA earnings call for the period ending June 30, 2021.
AKBA earnings call for the period ending September 30, 2020.
AKBA earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
